OrbiMed’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

OrbiMed’s Portfolio SPPI Stock Details SPPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,265,500	Closed	-$19.8M	–	147
2018 Q4	$19.8M	Hold	2,265,500	–	–	0.37%	69
2018 Q3	$38.1M	Buy	+2,265,500	New	+$49M	0.46%	63

Other funds holding SPPI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed's SPPI Position: Q1 2019 in Review

OrbiMed sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q1 2019, closing a stake of 2,265,500 shares — an estimated $19.8M sold.

OrbiMed first reported a position in SPPI in Q3 2018 and held it in 2 quarters. The position peaked at $38.1M in Q3 2018. 173 funds tracked by Wall St. Rank hold SPPI as of Q1 2019.

OrbiMed reported no remaining Spectrum Pharmaceuticals Inc position as of Q1 2019 after selling out during the quarter.
OrbiMed sold 2,265,500 Spectrum Pharmaceuticals Inc shares in Q1 2019, an estimated $19.8M.
OrbiMed first reported a position in Spectrum Pharmaceuticals Inc in Q3 2018 and held it in 2 quarters.
OrbiMed's Spectrum Pharmaceuticals Inc position peaked at $38.1M in Q3 2018.
173 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q1 2019.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.